Eli Lilly (LLY) Eyes the $1,400 Level With +15% Upside Potential
Key Takeaways
- Price target in focus: $1,400 represents a widely discussed analyst target and a logical next milestone for Eli Lilly and Company (LLY), implying roughly 15% upside from recent levels near $1,215.
- Strongest bullish factors: An industry-leading portfolio of GLP-1 drugs, a historic $27 billion manufacturing expansion, and expanding insurance coverage are creating a powerful revenue flywheel.
- Biggest risks: A premium valuation with a price-to-earnings (P/E) ratio above 43 leaves little room for error, while competition from Novo Nordisk (NVO) and potential pricing pressures could slow momentum.
- Key technical levels: The all-time high near $1,249 serves as immediate resistance, while the psychologically important $1,200 area and the $1,100 zone represent major support levels.
- Bottom line for investors: The path to $1,400 is supported by strong fundamentals and broad analyst conviction, but reaching that level will require continued flawless execution on manufacturing scale-up and product launches.
Why the $1,400 Level Matters
The $1,400 price target has become a focal point for Eli Lilly and Company (LLY) investors in 2026. Multiple major Wall Street firms, including J.P. Morgan and Barclays, have recently raised their 12-month price targets to exactly $1,400, while RBC Capital went even higher to $1,500. With the stock trading near $1,215 and having recently touched an all-time high of $1,249.45, the question of whether LLY can reach $1,400 has moved from theoretical to tangible. The target represents not just a round number but a level that would require the company's obesity and diabetes drug franchise to continue its remarkable growth trajectory.
Current Market Position
Eli Lilly and Company (LLY) has established itself as the most valuable healthcare company in the world, with a market capitalization exceeding $1.1 trillion. The stock has delivered a total return of approximately 54% over the past year, driven by explosive demand for its GLP-1 receptor agonist drugs. The company's first-quarter 2026 results underscored this momentum: earnings per share (EPS) of $8.55 crushed analyst estimates of $6.79, while revenue of $19.80 billion represented a year-over-year increase of more than 27%. The company's trailing 12-month revenue stands at $72.25 billion, with net income of $25.28 billion reflecting a net profit margin of roughly 35%.
What Could Drive the Next Leg Higher
The bull case for LLY reaching $1,400 rests on three pillars. First, the company's GLP-1 franchise continues to expand. The April 2026 approval of Foundayo (orforglipron), the first oral GLP-1 pill for weight management that can be taken without food or water restrictions, opens a vastly larger addressable market. Unlike injectable treatments that require refrigeration and needles, a daily pill removes significant barriers to adoption. Eli Lilly began shipping Foundayo through its LillyDirect platform within days of approval, with self-pay pricing starting near $149 per month for the lowest dose.
Second, the company is building supply ahead of demand. Management has committed $27 billion to four new U.S. manufacturing sites, with three focused on small-molecule production for pills like Foundayo. This represents what leadership has called the largest pharmaceutical expansion in U.S. history and signals deep conviction in future demand.
Third, access is widening rapidly. Eli Lilly reached an agreement to lower costs for Medicare beneficiaries, who can now pay as little as $50 per month for Zepbound and Foundayo. Commercial savings cards near $25 per month further reduce friction. Every dollar of cost removed converts hesitant patients into filled prescriptions, compounding into revenue growth.
What Could Prevent the Move
Despite the powerful growth narrative, several obstacles could keep $1,400 out of reach. Valuation is the most immediate concern. At a trailing P/E ratio above 43 and a forward P/E near 33, the stock already prices in substantial future growth. Any stumble in a product launch, a disappointing clinical trial readout, or slower-than-expected manufacturing scale-up could trigger a sharp multiple compression.
Competition remains fierce. Novo Nordisk (NVO) is fighting to defend its own obesity drug franchise, and a potential price war between the two dominant players could pressure margins as both chase the same patient population. Regulatory and political scrutiny over drug pricing also represents a persistent overhang. Building four manufacturing plants simultaneously carries significant execution risk that will not be resolved within a single year.
Analyst Opinions and Price Targets
Wall Street remains overwhelmingly bullish on Eli Lilly and Company (LLY). Of 30 analysts covering the stock, 23 rate it a Buy, 2 rate it a Strong Buy, 4 rate it a Hold, and only 1 carries a Sell rating. The consensus 12-month price target stands at approximately $1,260, but the range is wide: from a low of $850 at HSBC to a high of $1,500 at Citi and RBC Capital. Notably, J.P. Morgan, Barclays, and several other major firms have set targets at or above $1,400. The upward trajectory of these targets—many have been raised multiple times in 2026—reflects growing confidence in the company's ability to convert its drug pipeline into sustained revenue growth.
Technical Levels That Matter
From a technical analysis perspective, LLY is in a well-defined long-term uptrend. The stock recently hit an all-time high of $1,249.45, and a decisive breakout above that level would likely open the path toward $1,300 and eventually $1,400. The $1,200 area, which previously acted as resistance, has now become a critical support zone. Below that, the $1,100 level represents a more significant support area that aligns with prior consolidation. The 52-week low of $623.78, set in August 2025, underscores the magnitude of the rally but also serves as a reminder that even the strongest uptrends can experience sharp corrections. One thing that stands out when reviewing the chart is how cleanly the stock has held above key moving averages throughout this advance.
Using AI Daily Buy/Sell Signals
For traders seeking to navigate Eli Lilly's price movements with greater precision, AI Daily Buy/Sell Signals from Tickeron offer a data-driven approach. This platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Rather than relying solely on static analyst targets, traders can use these dynamic signals to identify emerging opportunities, monitor existing positions, and detect shifting market trends more efficiently. The tool is designed to help both active traders and longer-term investors stay ahead of changing market conditions without requiring constant manual chart analysis. I find it useful to cross-reference these signals with fundamental developments when evaluating positions like LLY.
Final Assessment
The $1,400 price target for Eli Lilly appears realistic but not guaranteed. The company possesses one of the strongest growth narratives in the pharmaceutical industry, backed by a portfolio of drugs addressing enormous global markets in diabetes and obesity. The transition from injectable to oral GLP-1 treatments through Foundayo represents a genuine inflection point that could expand the addressable patient population by multiples. Manufacturing investments and insurance coverage expansions are removing the two biggest barriers to adoption: supply constraints and cost. However, the stock's premium valuation means that any misstep will be punished. Investors should monitor quarterly prescription trends for Foundayo, manufacturing milestone updates, and any signs of pricing pressure from competitors or regulators. The path to $1,400 is visible, but it requires Eli Lilly to continue executing at an exceptionally high level. In my view, this remains one of the more compelling setups in the sector provided execution stays on track.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
LLY sees MACD Histogram crosses below signal line
LLY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 33 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 73%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In 53 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
LLY moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LLY crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for LLY entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LLY's RSI Oscillator exited the oversold zone, 18 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +0.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 263 of 376 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 12 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 65, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.153) is normal, around the industry mean (19.199). P/E Ratio (39.771) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). LLY has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.025). LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement